| Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi-institutional analysis WJ Magnuson, NH Lester-Coll, AJ Wu, TJ Yang, NA Lockney, NK Gerber, ... Journal of clinical oncology 35 (10), 1070-1077, 2017 | 466 | 2017 |
| Laser Interstitial Thermal Therapy in the Management of Brain Metastasis and Radiation Necrosis after Radiosurgery: An overview GHBAMM Mayur Sharma, Suresh Balasubramanian, Danilo Silva Expert Review of Neurotherapeutics,, 2016 | 99 | 2016 |
| Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer M Nagasaka, MH Uddin, MN Al-Hallak, S Rahman, S Balasubramanian, ... Molecular Cancer 20, 1-16, 2021 | 81 | 2021 |
| Rational management approach to pure red cell aplasia SK Balasubramanian, M Sadaps, S Thota, M Aly, BP Przychodzen, ... Haematologica 103 (2), 221, 2018 | 79 | 2018 |
| Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution SK Balasubramanian, M Sharma, D Silva, V Karivedu, P Schmitt, ... Journal of neuro-oncology, 2016 | 42 | 2016 |
| Distinct clinical and biological implications of CUX1 in myeloid neoplasms M Aly, ZM Ramdzan, Y Nagata, SK Balasubramanian, N Hosono, ... Blood advances 3 (14), 2164-2178, 2019 | 37 | 2019 |
| Impact of EGFR mutation and ALK rearrangement on the outcomes of non–small cell lung cancer patients with brain metastasis SK Balasubramanian, M Sharma, VA Venur, P Schmitt, R Kotecha, ... Neuro-oncology 22 (2), 267-277, 2020 | 32 | 2020 |
| Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab T Badar, A Szabo, A Advani, M Wadleigh, S Arslan, MA Khan, I Aldoss, ... Blood Advances 4 (10), 2308-2316, 2020 | 30 | 2020 |
| Circular RNAs in acute myeloid leukemia V Singh, MH Uddin, JA Zonder, AS Azmi, SK Balasubramanian Molecular cancer 20, 1-10, 2021 | 25 | 2021 |
| Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms SK Balasubramanian, AS Azmi, J Maciejewski Leukemia 36 (3), 601-612, 2022 | 22 | 2022 |
| Fanconi anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML B Przychodzen, H Makishima, MA Sekeres, SK Balasubramanian, ... Oncotarget 9 (2), 2050, 2018 | 22 | 2018 |
| Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second … T Badar, A Szabo, S Dinner, M Liedtke, M Burkart, RM Shallis, ... Cancer 127 (7), 1039-1048, 2021 | 19 | 2021 |
| Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age JP Maciejewski, SK Balasubramanian Hematology 2014, the American Society of Hematology Education Program Book …, 2017 | 17 | 2017 |
| PAK4 and NAMPT as novel therapeutic targets in diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma HY Khan, MH Uddin, SK Balasubramanian, N Sulaiman, M Iqbal, ... Cancers 14 (1), 160, 2021 | 16 | 2021 |
| Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with inotuzumab ozogamicin T Badar, A Szabo, M Wadleigh, M Liedtke, S Arslan, C Siebenaller, ... Clinical Lymphoma Myeloma and Leukemia 20 (8), 556-560. e2, 2020 | 15 | 2020 |
| The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy T Bat, ON Abdelhamid, SK Balasubramanian, A Mai, T Radivoyevitch, ... British journal of haematology 182 (5), 730, 2018 | 15 | 2018 |
| Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic … T Badar, A Szabo, M Litzow, M Burkart, I Yurkiewicz, S Dinner, M Hefazi, ... Bone Marrow Transplantation 56 (8), 1998-2004, 2021 | 13 | 2021 |
| Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions S Thota, BJ Patel, M Sadaps, S Balasubramanian, S Sanikommu, ... British journal of haematology 183 (1), 133, 2018 | 13 | 2018 |
| Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms SK Balasubramanian, M Aly, Y Nagata, T Bat, BP Przychodzen, ... Leukemia 32 (2), 550-553, 2018 | 12 | 2018 |
| Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia W Bahaj, T Kewan, C Gurnari, A Durmaz, B Ponvilawan, I Pandit, ... Journal of Hematology & Oncology 16 (1), 91, 2023 | 11 | 2023 |
Manmeet Ahluwalia, MD, MBA, FASCOChief Scientific Officer, Chief of Medical Oncology, and Deputy Director, Miami Cancer Institute在 baptisthealth.net 的电子邮件经过验证
